ERBB2 and cancer: Although HER2+ breast cancer patients have a worse prognosis compared with HER2− cancer patients, the availability of the anti-HER2 monoclonal antibody trastuzumab has changed the natural history of this tumor, thus significantly improving the overall survival of HER2+ breast cancer patients4.